Loading
A phase 1/2 trial of AFNT-211 in pancreatic ductal adenocarcinoma, non-small-cell lung cancer and colorectal cancer, run by Affini-T Therapeutics, Inc., active and no longer recruiting.
Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor is a phase 1/2 interventional study registered as NCT06105021 by Affini-T Therapeutics, Inc., with 100 participants enrolled, started 2024-03-06 and due to reach its primary completion in 2025-12. Interventions recorded: AFNT-211.
Shares Pancreatic ductal adenocarcinoma, Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma, Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma, Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma, Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma, Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma, Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.